Skip to main content

Hector Rios Duro

Institutions of which they are part

Research technician
Kidney Physiopathology
Vall Hebron Institut de Recerca

Hector Rios Duro

Institutions of which they are part

Research technician
Kidney Physiopathology
Vall Hebron Institut de Recerca

Projects

Biomarcadores, dianas y soluciones terapéuticas para mejorar el cuidado de pacientes afectados de Hipomagnesemia Familiar con Hipercalciuria y Nefrocalcinosis (HFHNC).

IP: Gema Ariceta Iraola
Collaborators: Hector Rios Duro, Biomarcadores, dianas y soluciones terapéuticas para mejorar el cuidado de pacientes afectados de Hipomagnesemia Familiar con H, Julieta Torchia Pruzzo, Gloria Mª Fraga Rodriguez
Funding agency: Instituto de Salud Carlos III
Funding: 202070
Reference: PI22/01946
Duration: 01/01/2023 - 30/06/2027

Papel del ClC-5 en la fibrosis renal. Identificación de posibles biomarcadores y dianas terapéuticas para la progresión de la enfermedad de Dent 1

IP: Gerard Cantero Recasens
Collaborators: Anna Meseguer Navarro, Andrea Casal Pardo, Hector Rios Duro, Papel del ClC-5 en la fibrosis renal. Identificación de posibles biomarcadores y dianas terapéuticas para la progresión de la e, Julieta Torchia Pruzzo, Gloria Mª Fraga Rodriguez
Funding agency: Instituto de Salud Carlos III
Funding: 123420
Reference: PI22/00741
Duration: 01/01/2023 - 30/06/2027

Patologia Cel·lular

IP: Patologia Cel·lular
Collaborators: Gema Ariceta Iraola, Alejandro Cruz Gual, Gerard Cantero Recasens, David Lorente García, Marina Muñoz López, Mercedes López González, Hector Rios Duro, Patologia Cel·lular, Luis Augusto Castro Sáder, Gloria Mª Fraga Rodriguez, Julieta Torchia
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 01600
Duration: 01/01/2022 - 30/06/2025

Related news

The Oliver Wrong Research Award, granted by the Dent Disease Foundation, will fund a project combining kidney organoids and artificial intelligence to identify potential treatments for this rare kidney disease.

The team has discovered that a protein called SEC22B acts as a phenotype modifier and could be used as a potential urinary marker of the disease.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Sofia Chica Muñoz de Leon

Sofia Chica Muñoz de Leon

Research technician
Clinical Neuroimmunology
Read more
Nuria Vallejo Camazón

Nuria Vallejo Camazón

Senior researcher
Cardiovascular Diseases
Read more
Sara Bayarri Fresquet

Sara Bayarri Fresquet

Gestió i Administració
Teaching Unit
Internal Strategy Directorate
Read more
Javier Martí Ruiz

Javier Martí Ruiz

Predoctoral researcher
Multidisciplinary Nursing Research Group
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.